AbbVie, Voyager to develop single gene therapy for Alzheimer’s
AbbVie and Voyager Therapeutics are joining forces to develop a new therapy for Alzheimer’s disease and other neurodegenerative conditions.
Read More
Tag: vectorised antibodies
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
- Gedeon Richter UK takes over UK rights to cariprazine
- Otsuka Pharmaceutical’s Dawnzera receives EC approval for hereditary angioedema prevention
